Clinical and experimental rationale for antioxidant therapy of chronic bacterial prostatitis
| Autor: | Pavel A. Dubonos, Igor A. Tyuzikov, Oleg I. Bratchikov |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
antioxidant
Antioxidant medicine.medical_treatment 030232 urology & nephrology RM1-950 Pharmacology Lipid peroxidation Superoxide dismutase 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine antihypoxant Antimicrobial chemotherapy medicine Pharmacology (medical) antimicrobial chemotherapy free radical oxidation experimental simulation biology business.industry Succinate dehydrogenase zinc lipid peroxidation Chronic bacterial prostatitis experimental simulation antimicrobial chemotherapy free radical oxidation lipid peroxidation superoxide dismutase succinate dehydrogenase antioxidant antihypoxant zinc L-carnitine succinate dehydrogenase medicine.disease superoxide dismutase L-carnitine Chronic bacterial prostatitis chemistry 030220 oncology & carcinogenesis Free radical oxidation biology.protein Therapeutics. Pharmacology business |
| Zdroj: | Research Results in Pharmacology, Vol 6, Iss 1, Pp 11-19 (2020) Research Results in Pharmacology 6(1): 11-19 |
| Popis: | Introduction: Literature data prove the important role of oxidative stress in the pathogenesis of Chronic Bacterial Prostatitis (CBP) and its recurrence, which reduces the effectiveness of standard etiotropic therapy of the disease. Aim of study: To improve the results of the pharmacotherapy of CBP by a comprehensive assessment of oxidative disorders in the prostate gland in a clinical and experimental study to provide evidence for antioxidant support. Material and methods: The results of experimental simulation of CBP in 60 male rats and examination of 90 patients with CBP (average age 38.2 ± 1.4; main group) and 30 clinically healthy men (average age 35.5±1.5; control group), which included history-taking, collecting complaints, questioning, general and special examinations, biochemical, cytological, microbiological, sonographic studies. In some experimental animals and patients with CBP, different modes of pharmacotherapy were tested (antimicrobial monochemotherapy; antimicrobial chemotherapy+zinc picolinate; antimicrobial chemotherapy+L–carnitine tartrate in standard doses). The data were processed using descriptive and comparative statistics. Results and discussion: Clinical and experimental findings showed the compensatory nature of the prostatic oxidative disorders after a standard antimicrobial monochemotherapy of the first episode of CBP and their continued persistence with a high risk of decompensation and development of mitochondrial dysfunction after a course of standard antimicrobial monochemotherapy in CBP recurrence. Zinc deficiency in the patients with CBP was detected on average 2.7 times more often than in the healthy men, so zinc determination in the prostatic fluid and subsequent drug compensation should be considered as first–line diagnostic and treatment measures. In the patients with CBP without zinc deficiency, L-carnitine may be an effective alternative to pharmacological correction of the prostatic oxidative disorders. Conclusion: To increase the effectiveness of standard etiotropic therapy of CBP, simultaneous antioxidant support is necessary, using differentiated administration of antioxidants/antihypoxants (zinc or L-carnitine). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|